Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
| ▸ | CCNC | P24863 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793294 | 1.00 | CXCL8 (0.55) | CXCL8RAB9ANPC1SMN1; SMN2MAPK10 | |
| SCHEMBL3607119 | 0.85 | MAPT (0.56) | CXCL8RAB9ANPC1SMN1; SMN2MAPK10 | |
| SCHEMBL29414658 | 0.85 | MAPT (0.56) | CXCL8RAB9ANPC1SMN1; SMN2MAPK10 | |
| SCHEMBL15129488 | 0.85 | TSHR (0.48) | CXCL8RAB9ANPC1SMN1; SMN2MAPK10 | |
| SCHEMBL14928325 | 0.85 | ACHE (0.54) | CXCL8RAB9ANPC1SMN1; SMN2MAPK10 | |
| SCHEMBL30785818 | 0.84 | MAPT (0.56) | CXCL8RAB9ANPC1SMN1; SMN2MAPK10 | |
| SCHEMBL1704615 | 0.84 | MAPT (0.56) | CXCL8RAB9ANPC1SMN1; SMN2MAPK10 | |
| SCHEMBL3147287 | 0.83 | CXCL8 (0.44) | CXCL8RAB9ANPC1SMN1; SMN2MAPK10 | |
| SCHEMBL17110620 | 0.82 | POLB (0.56) | RAB9ANPC1SMN1; SMN2MAPK10KDM4E | |
| SCHEMBL16481466 | 0.82 | FABP3 (0.55) | CXCL8RAB9ANPC1SMN1; SMN2MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288504-A1 | Ligands for metals as catalysts for carbon-carbon bond formation | NATIONAL SUN YAT-SEN UNIVERSITY | 2005-12-29 | — | — | US | claimed |
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-03-17 | — | — | US | disclosed |
| EP-4365180-A1 | RARE EARTH COMPLEX | Tosoh Corporation (JP) | 2024-05-08 | — | — | EP | disclosed |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| CN-117616032-A | Rare earth complex | 东曹株式会社 | 2024-02-27 | — | — | CN | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| WO-2023224853-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
| US-6482765-B1 | Modified particles, carrier prepared therefrom, olefin polymerization catalyst component prepared therefrom, olefin polymerization catalyst prepared therefrom, and process for preparing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-11-19 | — | — | US | disclosed |
| US-20020143124-A1 | Homogeneous type solid catalyst component or homogeneous type solid catalyst, process for production thereof and process for producing addition polymer with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-03 | — | — | US | disclosed |
| EP-1153938-A1 | CATALYST FOR STEREOREGULAR POLYMERIZATION OF ALPHA-OLEFIN AND PROCESS FOR PRODUCING STEREOREGULAR ALPHA-OLEFIN POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-11-14 | — | — | EP | disclosed |
| US-20010020075-A1 | Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-09-06 | — | — | US | disclosed |
| US-6284699-B1 | COORDINATION POLYMERIZATION CATALYSTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-09-04 | — | — | US | disclosed |
| EP-1114832-A1 | Modified particles, catalyst for olefin polymerization using the same, and process of producing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-07-11 | — | — | EP | disclosed |
| US-20010007007-A1 | Modified particles, catalyst for olefin polymerization using the same, and process of producing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-07-05 | — | — | US | disclosed |
| EP-1113026-A2 | Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-07-04 | — | — | EP | disclosed |
| EP-0949273-A1 | MODIFIED PARTICLES, CARRIER PREPARED THEREFROM, OLEFIN POLYMERIZATION CATALYST COMPONENT PREPARED THEREFROM, OLEFIN POLYMERIZATION CATALYST PREPARED THEREFROM, AND PROCESS FOR PREPARING OLEFIN POLYMER | Sumitomo Chemical Company, Limited (JP) | 1999-10-13 | — | — | EP | disclosed |
| EP-0082658-A2 | Processes and intermediates useful in the preparation of flutroline | PFIZER INC. (US) | 1983-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | CD38, PARP9, MCCC2 | CXCL8 4800/4885RAB9A 2004/4885NPC1 4413/4885 |
| US-20230373919-A1 | AT2R ANTAGONISTS AND USES THEREOF | AGTR2, AGTR1, AVPR2 | CXCL8 2078/4885RAB9A 2255/4885NPC1 2373/4885 |
| US-20050288504-A1 | Ligands for metals as catalysts for carbon-carbon bond formation | NCOR2, NCOR1, NR1I2 | CXCL8 4506/4885RAB9A 3871/4885NPC1 999/4885 |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | CXCL8 4588/4885RAB9A 2634/4885NPC1 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.